These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 27208464)

  • 1. Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study.
    Van Belle E; Hengstenberg C; Lefevre T; Kupatt C; Debry N; Husser O; Pontana F; Kuchcinski G; Deliargyris EN; Mehran R; Bernstein D; Anthopoulos P; Dangas GD;
    J Am Coll Cardiol; 2016 Aug; 68(6):589-599. PubMed ID: 27208464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
    Dangas GD; Lefèvre T; Kupatt C; Tchetche D; Schäfer U; Dumonteil N; Webb JG; Colombo A; Windecker S; Ten Berg JM; Hildick-Smith D; Mehran R; Boekstegers P; Linke A; Tron C; Van Belle E; Asgar AW; Fach A; Jeger R; Sardella G; Hink HU; Husser O; Grube E; Deliargyris EN; Lechthaler I; Bernstein D; Wijngaard P; Anthopoulos P; Hengstenberg C;
    J Am Coll Cardiol; 2015 Dec; 66(25):2860-2868. PubMed ID: 26477635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Linke A; Chandrasekhar J; Sartori S; Lefevre T; van Belle E; Schaefer U; Tchetche D; Sardella G; Webb J; Colombo A; Windecker S; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Asgar A; Dumonteil N; Tamburino C; Hink U; Violini R; Stella P; Bernstein D; Deliargyris E; Hengstenberg C; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1016-1026. PubMed ID: 28498562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
    Asgar A; Chandrasekhar J; Mikhail G; Webb J; Lefèvre T; Tamburino C; Hildick-Smith D; Hambrecht R; Van Belle E; Widder J; Dumonteil N; Hink U; Jeger R; Linke A; Deliargyris E; Gao P; Mehran R; Hengstenberg C; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):144-153. PubMed ID: 27152677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
    Zilberszac R; Chandiramani R; Hengstenberg C; Sartori S; Cao D; Chandrasekhar J; Schafer U; Tchetche D; Violini R; Jeger R; Van Belle E; Boekstegers P; Hambrecht R; Tron C; Dumenteil N; Linke A; Ten Berg JM; Deliargyris EN; Anthopoulos P; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E377-E386. PubMed ID: 31808295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Hengstenberg C; Chandrasekhar J; Sartori S; Lefevre T; Mikhail G; Meneveau N; Tron C; Jeger R; Kupatt C; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Husser O; Boekstegers P; Hambrecht R; Widder J; Hildick-Smith D; De Carlo M; Wijngaard P; Deliargyris E; Bernstein D; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1027-1037. PubMed ID: 28493641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial.
    Chandrasekhar J; Sartori S; Mehran R; Aquino M; Vogel B; Asgar AW; Webb JG; Tchetche D; Dumonteil N; Colombo A; Windecker S; Claessen BE; Ten Berg JM; Hildick-Smith D; Wijngaard P; Lefèvre T; Deliargyris EN; Hengstenberg C; Anthopoulos P; Dangas GD
    Clin Res Cardiol; 2021 May; 110(5):649-657. PubMed ID: 33839885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement.
    Latib A; Mangieri A; Vezzulli P; Spagnolo P; Sardanelli F; Fellegara G; Pagnesi M; Giannini F; Falini A; Gorla R; Montorfano M; Bedogni F; Colombo A; Popma J; Merhi WM; De Marco F
    JACC Cardiovasc Interv; 2020 Apr; 13(7):860-868. PubMed ID: 32273098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study.
    Rodés-Cabau J; Kahlert P; Neumann FJ; Schymik G; Webb JG; Amarenco P; Brott T; Garami Z; Gerosa G; Lefèvre T; Plicht B; Pocock SJ; Schlamann M; Thomas M; Diamond B; Merioua I; Beyersdorf F; Vahanian A
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1146-55. PubMed ID: 25341709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Fibrin Polymerization During Bivalirudin Anticoagulation for Transcatheter Aortic Valve Replacement.
    Wipfli C; Fitzpatrick MV; Fitzpatrick JK; Taylor BS; Tanaka KA
    J Cardiothorac Vasc Anesth; 2017 Aug; 31(4):e65-e66. PubMed ID: 28583422
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
    Feldman D; Cao D; Sartori S; Zhang Z; Hengstenberg C; Tron C; Anthopoulos P; Widder JD; Meneveau N; Stella PR; Ferrari M; Jeger R; Violini R; Dumonteil N; Chen S; Yan R; Nicolas J; Razuk V; Spirito A; Vogel B; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2023 May; 101(6):1134-1143. PubMed ID: 37036268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfemoral Transcatheter Aortic Valve Replacement in a Patient With Heparin-Induced Thrombocytopenia: Intraoperative Anticoagulation Management With Bivalirudin (Angiomax).
    Scott B; Tam CW; Moon RS
    J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1603-5. PubMed ID: 25604599
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploring the Difference in Post-procedural Stroke Rates Between Patients with Aortic Stenosis Who Undergo Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement.
    Burke H; Boron A; Lee JH; Kahlon KR
    Cureus; 2018 Apr; 10(4):e2494. PubMed ID: 29922535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silent ischemic brain lesions after transcatheter aortic valve replacement: lesion distribution and predictors.
    Samim M; Hendrikse J; van der Worp HB; Agostoni P; Nijhoff F; Doevendans PA; Stella PR
    Clin Res Cardiol; 2015 May; 104(5):430-8. PubMed ID: 25596724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
    Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
    Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.
    Camaj A; Claessen BE; Mehran R; Yudi MB; Power D; Baber U; Hengstenberg C; Lefevre T; Van Belle E; Giustino G; Guedeney P; Sorrentino S; Kupatt C; Webb JG; Hildick-Smith D; Hink HU; Deliargyris EN; Anthopoulos P; Sharma SK; Kini A; Sartori S; Chandrasekhar J; Dangas GD
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E688-E694. PubMed ID: 31943717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation.
    Lange P; Greif M; Bongiovanni D; Thaumann A; Näbauer M; Bischoff B; Helbig S; Becker C; Schmitz C; D'Anastasi M; Mehilli J; Boekstegers P; Massberg S; Kupatt C
    Can J Cardiol; 2015 Aug; 31(8):998-1003. PubMed ID: 26211708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TriGuard
    Samim M; van der Worp B; Agostoni P; Hendrikse J; Budde RP; Nijhoff F; Ramjankhan F; Doevendans PA; Stella PR
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):470-477. PubMed ID: 27121306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.
    Razuk V; Camaj A; Cao D; Nicolas J; Hengstenberg C; Sartori S; Zhang Z; Power D; Beerkens F; Chiarito M; Meneveau N; Tron C; Dumonteil N; Widder JD; Ferrari M; Violini R; Stella PR; Jeger R; Anthopoulos P; Mehran R; Dangas GD
    Catheter Cardiovasc Interv; 2021 Nov; 98(6):E870-E880. PubMed ID: 33909348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Embolic protection in patients undergoing transaortic transcatheter aortic valve replacement: initial experience with the TriGuard HDH embolic deflection device.
    Campelo-Parada F; Regueiro A; Dumont E; DeLarochellière R; Paradis JM; Mohammadi S; Doyle D; Rodés-Cabau J
    J Card Surg; 2016 Oct; 31(10):617-622. PubMed ID: 27577965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.